TON - May 2017, Vol 10, No 3

Awareness of the adverse effects of immune checkpoint inhibitors and how to manage them was the focus of several presentations at the National Comprehensive Cancer Network (NCCN) 22nd Annual Conference. Read More ›

The results of a new study presented at the 2017 Genitourinary Cancers Symposium suggest that recent use of antibiotics may compromise the efficacy of immunotherapy. Read More ›

The current practice in the treatment of advanced kidney cancer and some other cancers is to continue treatment with immune checkpoint inhibitors until disease progression, and sometimes even longer. Read More ›

  • Venetoclax plus Rituximab Improves Outcomes in Chronic Lymphocytic Leukemia
  • Lay Navigation Reduces Medicare Costs, Resource Utilization
  • Adding Antiandrogen Therapy Improves Survival in Recurrent Prostate Cancer
Read More ›

Following a year in which approximately 2 dozen cancer drugs were approved by the FDA, approvals in 2016 decreased by approximately 50% compared with 2015. Read More ›

In recognition of the distress associated with the diagnosis and treatment of cancer, the National Comprehensive Cancer Network (NCCN) has produced several resources to help patients report their distress and cope with it. Read More ›

Adolescents and young adults (AYAs) with cancer often wait too long to discuss their end-of-life preferences, or they do not discuss those preferences at all and pass away in a manner that is against their wishes. Read More ›

Providers caring for dying patients should be prepared to discuss physician-assisted death (PAD). Read More ›

Page 2 of 2

Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: